CAS-1Homo sapiens (Human)Cancer cell line

Also known as: CAS1

🤖 AI SummaryBased on 7 publications

Quick Overview

Human cancer cell line with potential for research in cancer biology and drug development.

Detailed Summary

CAS-1 is a human cancer cell line derived from a glioblastoma (WHO grade IV). It is used in research to study the molecular mechanisms of cancer and to develop new therapeutic strategies. The cell line is part of the Cancer Cell Line Encyclopedia (CCLE) and has been characterized for its genetic and molecular profiles. CAS-1 is utilized in studies involving drug sensitivity, genomic alterations, and cancer biology. It is also used to investigate the role of specific genes and pathways in cancer progression and response to treatment.

Research Applications

Cancer biology researchDrug developmentGenomic profilingDrug sensitivity studies

Key Characteristics

Part of the Cancer Cell Line Encyclopedia (CCLE)Used in studies of cancer genetics and molecular mechanismsUtilized for drug sensitivity and resistance research

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1117
Species	Homo sapiens (Human)
Tissue Source	Brain[UBERON:UBERON_0000955]

Donor Information

Age	63
Age Category	Adult
Sex	Male

Disease Information

Disease	Glioblastoma
Lineage	CNS/Brain
Subtype	Glioblastoma
OncoTree Code	GB

DepMap Information

Source Type	ICLC
Source ID	ACH-000464_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg248Trp (c.742C>T)	Homozygous	Somatic mutation acquired during proliferation	from parent cell line VCaP

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

D13S317

8,10

D16S539

9,14

D5S818

D7S820

8,12

TH01

6,9

TPOX

vWA

14,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Chemosensitivity of glioblastoma cells during treatment with the organo-tin compound triethyltin(IV)lupinylsulfide hydrochloride.

Alama A.

J. Neurooncol. 60:109-116(2002).

DOI PubMed